Study on sleep and advanced Parkinson's with foslevodopa/foscarbidopa
Part of Brain & nervous system clinical trials.
This study looks at how a Parkinson's drug delivered under the skin (foslevodopa/foscarbidopa) affects sleep problems in people with advanced Parkinson's. It is a real-world study that follows your usual treatment, no new experimental drug is being tested.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older with advanced Parkinson's disease that responds to levodopa.
- You are currently using foslevodopa/foscarbidopa as a continuous infusion under the skin (prescribed by your doctor).
- Your thinking and memory are good enough to follow study instructions (test score of 24 or higher on a memory exam).
- If you have moderate to severe sleep apnea, you must be using your CPAP or mouth device correctly (at least 4 hours per night, 70% of nights).
- You are not taking part in any other interventional research study at this time.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new single-dose treatment for Parkinson's disease to see if it can help reduce 'off' time—when medication wears off and symptoms return. It is for people who experience motor fluctuations and are already on a stable medication routine.
This study looks at a new pump treatment (foslevodopa/foscarbidopa) for people with advanced Parkinson's who are having motor fluctuations. It aims to see if it improves quality of life when started earlier in the advanced stage.
This study looks at how well a treatment called foslevodopa/foscarbidopa works for people with advanced Parkinson's disease. It is given as a shot under the skin (subcutaneous) and is already being used in clinics. The study will follow people who are already starting this treatment as part of their regular care.
This study is looking at how a new continuous 24-hour injection treatment (foslevodopa/foscarbidopa) affects quality of life in people with advanced Parkinson's disease. It is a real-world study, meaning you just take the medication as your doctor prescribes, and researchers observe the results.
This study observes how well a new type of levodopa/carbidopa treatment works in real-world practice for people with advanced Parkinson's disease who are already using it. It aims to understand patient experiences and the support program offered by the drug maker.
This study tests a new pump-delivered combination of Parkinson's medications (foslevodopa/foscarbidopa) in adults who have recently started having motor fluctuations but are not yet using other device therapies. It aims to see how well it works in real life and may offer better symptom control.
Hear when a new Advanced Parkinson's Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.